All Press Releases
PILA PHARMA ANNOUNCES PRE-CLINICAL OBESITY AND AMYLIN SPECIALIST PROFESSOR THOMAS LUTZ TO JOIN AS SCIENTIFIC ADVISER
Malmö, 04 December 2025 PILA PHARMA AB (publ) (FN STO: PILA) informs that Professor Thomas Lutz DVM, PhD, University of Zurich, Switzerland is now joining PILA PHARMA’s Scientific Advisory Board. Professor Thomas Lutz MD, PhD is a leading pre-clinical researcher in obesity and metabolic diseases that since the 1990’ies has been working in the field of research on the regulation…
PILA PHARMA: UPCOMING PARTICIPATION IN OBESITYWEEK AND AMERICAN HEART ASSOCIATION CONVENTION
Malmö, 27 October 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, informs of its participation in two upcoming scientific conferences in the United States. 04-07 November: ObesityWeek® by The Obesity Society (TOS)Atlanta, United Stateshttps://obesityweek.org/ 07-10 November: American Heart Association® Convention (AHA) New Orleans, United Stateshttps://professional.heart.org/en/meetings/scientific-sessions…
PILA PHARMA: CEO GUSTAV H. GRAM ACQUIRES ADDITIONAL SHARES
Malmö, 07 October 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors and others with interest in the space that CEO Gustav H. Gram has increased his shareholding in the company. Mr. Gram acquired a total of 36,677 shares in PILA PHARMA AB…